Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819232 | 1.00 | CASP3 (0.44) | CASP3KMT2AMDM2TP53MDM4 | |
| SCHEMBL29424162 | 0.90 | MDM2 (0.38) | CASP3MDM2TP53MDM4MAPT | |
| SCHEMBL23728631 | 0.89 | CASP3 (0.44) | CASP3KMT2AMDM2TP53MDM4 | |
| SCHEMBL15281424 | 0.89 | CASP3 (0.44) | CASP3KMT2AMDM2TP53MDM4 | |
| SCHEMBL872752 | 0.89 | CASP3 (0.44) | CASP3KMT2AMDM2TP53MDM4 | |
| SCHEMBL29424172 | 0.88 | CASP3 (0.39) | CASP3KMT2ATP53MDM4MAPT | |
| SCHEMBL31498725 | 0.83 | MDM2 (0.38) | CASP3MDM2TP53MDM4MAPT | |
| SCHEMBL19986214 | 0.83 | KMT2A (0.41) | KMT2ATP53MAPT | |
| SCHEMBL25272091 | 0.82 | CASP3 (0.45) | CASP3KMT2ATP53MDM4 | |
| SCHEMBL25223099 | 0.82 | CASP3 (0.45) | CASP3KMT2ATP53MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| WO-2019055444-A1 | BET BROMODOMAIN PROTEIN DEGRADERS WITH CLEAVABLE LINKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | BRD4, BET1, BRWD1 | CASP3 2258/4885KMT2A 170/4885MDM2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.